标题/作者	年份
Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics Y Wang, S Zhang, F Li, Y Zhou, Y Zhang, Z Wang, R Zhang, J Zhu, Y Ren, ... Nucleic acids research 48 (D1), D1031-D1041	2020
Development of the inhibitors that target the PD-1/PD-L1 interaction—a brief look at progress on small molecules, peptides and macrocycles K Guzik, M Tomala, D Muszak, M Konieczny, A Hec, U Błaszkiewicz, ... Molecules 24 (11), 2071	2019
CA-170–a potent small-molecule PD-L1 inhibitor or not? B Musielak, J Kocik, L Skalniak, K Magiera-Mularz, D Sala, M Czub, ... Molecules 24 (15), 2804	2019
Comprehensive in vitro characterization of PD-L1 small molecule inhibitors A Ganesan, M Ahmed, I Okoye, E Arutyunova, D Babu, WL Turnbull, ... Scientific reports 9 (1), 12392	2019
Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules X Lin, X Lu, G Luo, H Xiang European journal of medicinal chemistry 186, 111876	2020
Combination of bacterial‐photothermal therapy with an anti‐PD‐1 peptide depot for enhanced immunity against advanced cancer W Chen, Z Guo, Y Zhu, N Qiao, Z Zhang, X Sun Advanced functional materials 30 (1), 1906623	2020
Rationally designed peptide-conjugated gold/platinum nanosystem with active tumor-targeting for enhancing tumor photothermal-immunotherapy Q Yang, J Peng, K Shi, Y Xiao, Q Liu, R Han, X Wei, Z Qian Journal of Controlled Release 308, 29-43	2019
Design, synthesis, evaluation, and structural studies of C 2-symmetric small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 protein–protein interaction S Basu, J Yang, B Xu, K Magiera-Mularz, L Skalniak, B Musielak, ... Journal of Medicinal Chemistry 62 (15), 7250-7263	2019
Discovery of [1, 2, 4] triazolo [4, 3-a] pyridines as potent inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 interaction M Qin, Q Cao, S Zheng, Y Tian, H Zhang, J Xie, H Xie, Y Liu, Y Zhao, ... Journal of Medicinal Chemistry 62 (9), 4703-4715	2019
Research status and outlook of PD-1/PD-L1 inhibitors for cancer therapy L Ai, J Chen, H Yan, Q He, P Luo, Z Xu, X Yang Drug design, development and therapy, 3625-3649	2020
Polymer nanomedicines J Kopeček, J Yang Advanced drug delivery reviews 156, 40-64	2020
Adenosine A2A receptor antagonists for cancer immunotherapy: Miniperspective F Yu, C Zhu, Q Xie, Y Wang Journal of Medicinal Chemistry 63 (21), 12196-12212	2020
Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing Z Wang, W Kang, O Li, F Qi, J Wang, Y You, P He, Z Suo, Y Zheng, ... Acta pharmaceutica sinica B 11 (3), 694-707	2021
Human and mouse PD-L1: similar molecular structure, but different druggability profiles K Magiera-Mularz, J Kocik, B Musielak, J Plewka, D Sala, M Machula, ... Iscience 24 (1)	2021
Di-bromo-based small-molecule inhibitors of the PD-1/PD-L1 immune checkpoint M Konieczny, B Musielak, J Kocik, L Skalniak, D Sala, M Czub, ... Journal of Medicinal Chemistry 63 (19), 11271-11285	2020
Discovery of the programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold M Qin, Q Cao, X Wu, C Liu, S Zheng, H Xie, Y Tian, J Xie, Y Zhao, Y Hou, ... European Journal of Medicinal Chemistry 186, 111856	2020
Role of small molecule targeted compounds in cancer: progress, opportunities, and challenges G Sun, D Rong, Z Li, G Sun, F Wu, X Li, H Cao, Y Cheng, W Tang, Y Sun Frontiers in cell and developmental biology 9, 694363	2021
Immune checkpoint inhibitors in melanoma: a review of pharmacokinetics and exposure–response relationships C Leven, M Padelli, JL Carré, E Bellissant, L Misery Clinical pharmacokinetics 58, 1393-1405	2019
Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: A review C Liu, NP Seeram, H Ma Cancer cell international 21 (1), 1-17	2021
Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation C Pan, H Yang, Y Lu, S Hu, Y Wu, Q He, X Dong European Journal of Medicinal Chemistry 213, 113170	2021

1 - 20

计算机程序会自动估算并确定日期和引用次数。